Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krupp, L. B.
Right arrow Articles by Grimson, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krupp, L. B.
Right arrow Articles by Grimson, R.

Neurology, Vol 45, Issue 11 1956-1961, Copyright © 1995 by American Academy of Neurology

ARTICLES

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

LB Krupp, PK Coyle, C Doscher, A Miller, AH Cross, L Jandorf, J Halper, B Johnson, L Morgante and R Grimson
Multiple Sclerosis Comprehensive Care Center, State University of New York (SUNY) at Stony Brook, USA.

OBJECTIVE: To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue. BACKGROUND: Fatigue is a complication of MS. Both pemoline and amantadine have been used to treat MS fatigue, but their relative efficacy is not known. METHODS: Amantadine, pemoline, and placebo were compared in a randomized, double-blind, placebo-controlled study using a parallel-group design. Ninety-three ambulatory MS patients completed the study. Primary outcome measures were the fatigue severity scale (FSS); the MS-specific fatigue scale (MS-FS); and subjective response determined by verbal self-report. Secondary outcome measures consisted of assessments of sleep, depression, and vitality. Repeated-measures analysis of variance with planned post-hoc contrasts and Fisher's exact test were used to compare treatment response. RESULTS: Amantadine- treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0.04). By verbal report at the end of the study, 79% of patients treated with amantadine versus 52% treated with placebo and 32% treated with pemoline preferred drug therapy compared with no treatment (p = 0.03). No significant differences in any primary outcome measures were noted between pemoline and placebo. Neither amantadine nor pemoline affected sleep or depression relative to placebo. CONCLUSION: Amantadine was significantly better than placebo in treating fatigue in MS patients, whereas pemoline was not. The benefit of amantadine was not due to changes in sleep, depression, or neurologic disability.


This article has been cited by other articles:


Home page
 Mult SclerHome page
C. Sauter, K. Zebenholzer, J. Hisakawa, J. Zeitlhofer, and K. Vass
A longitudinal study on effects of a six-week course for energy conservation for multiple sclerosis patients
Multiple Sclerosis, May 1, 2008; 14(4): 500 - 505.
[Abstract] [PDF]

Home page
 ChestHome page
E. E. Lower, S. Harman, and R. P. Baughman
Double-Blind, Randomized Trial of Dexmethylphenidate Hydrochloride for the Treatment of Sarcoidosis-Associated Fatigue
Chest, May 1, 2008; 133(5): 1189 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 Psychosom. Med.Home page
K. van Kessel, R. Moss-Morris, E. Willoughby, T. Chalder, M. H. Johnson, and E. Robinson
A Randomized Controlled Trial of Cognitive Behavior Therapy for Multiple Sclerosis Fatigue
Psychosom Med, February 1, 2008; 70(2): 205 - 213.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group
Treatment of pediatric multiple sclerosis and variants
Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
P. Scherer, I.K. Penner, A. Rohr, H. Boldt, I. Ringel, H. Wilke-Burger, E. Burger-Deinerth, K. Isakowitsch, M. Zimmermann, S. Zahrnt, et al.
The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study
Multiple Sclerosis, April 1, 2007; 13(3): 402 - 411.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M P J Garssen, P I M Schmitz, I S J Merkies, B C Jacobs, F G A van der Meche, and P A van Doorn
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 61 - 65.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. H. Adler and M. J. Thorpy
Sleep issues in Parkinson's disease
Neurology, June 28, 2005; 64(12_suppl_3): S12 - S20.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. R. Schwid and T. J. Murray
Treating fatigue in patients with MS: One step forward, one step back
Neurology, April 12, 2005; 64(7): 1111 - 1112.
[Full Text] [PDF]

Home page
 NeurologyHome page
B. Stankoff, E. Waubant, C. Confavreux, G. Edan, M. Debouverie, L. Rumbach, T. Moreau, J. Pelletier, C. Lubetzki, M. Clanet, et al.
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Neurology, April 12, 2005; 64(7): 1139 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
N Tellez, J Rio, M Tintore, C Nos, I Galan, and X Montalban
Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?
Multiple Sclerosis, April 1, 2005; 11(2): 198 - 202.
[Abstract] [PDF]

Home page
 Scand J Public HealthHome page
A. Lerdal, A. K. Wahl, T. Rustoen, B. R. Hanestad, and T. Moum
Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale
Scand J Public Health, March 1, 2005; 33(2): 123 - 130.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A. Romani, R. Bergamaschi, E. Candeloro, E. Alfonsi, R. Callieco, and V. Cosi
Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment
Multiple Sclerosis, August 1, 2004; 10(4): 462 - 468.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
H. P. Attarian, K. M. Brown, S. P. Duntley, J. D. Carter, and A. H. Cross
The Relationship of Sleep Disturbances and Fatigue in Multiple Sclerosis
Arch Neurol, April 1, 2004; 61(4): 525 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
M. C. Tartaglia, S. Narayanan, S. J. Francis, A. C. Santos, N. De Stefano, Y. Lapierre, and D. L. Arnold
The Relationship Between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis
Arch Neurol, February 1, 2004; 61(2): 201 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A Lerdal, E G Celius, and T Moum
Fatigue and its association with sociodemographic variables among multiple sclerosis patients
Multiple Sclerosis, October 1, 2003; 9(5): 509 - 514.
[Abstract] [PDF]

Home page
 Psychosom. Med.Home page
D. C. Mohr, S. L. Hart, and A. Goldberg
Effects of Treatment for Depression on Fatigue in Multiple Sclerosis
Psychosom Med, July 1, 2003; 65(4): 542 - 547.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. B. Krupp, L. G. Hyman, R. Grimson, P. K. Coyle, P. Melville, S. Ahnn, R. Dattwyler, and B. Chandler
Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial
Neurology, June 24, 2003; 60(12): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R. Bakshi
Fatigue associated with multiple sclerosis: diagnosis, impact and management
Multiple Sclerosis, June 1, 2003; 9(3): 219 - 227.
[Abstract] [PDF]

Home page
 Mult SclerHome page
P Flachenecker, T Kumpfel, B Kallmann, M Gottschalk, O Grauer, P Rieckmann, C Trenkwalder, and K V Toyka
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
Multiple Sclerosis, December 1, 2002; 8(6): 523 - 526.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
K W Rammohan, J H Rosenberg, D J Lynn, A M Blumenfeld, C P Pollak, and H N Nagaraja
Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 179 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A. J Thompson
SYMPTOMATIC MANAGEMENT AND REHABILITATION IN MULTIPLE SCLEROSIS
J. Neurol. Neurosurg. Psychiatry, December 1, 2001; 71(suppl_2): ii22 - ii27.
[Full Text] [PDF]

Home page
 AM J HOSP PALLIAT CAREHome page
N. Sarhill, D. Walsh, K. A. Nelson, J. Homsi, S. LeGrand, and M. P. Davis
Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study
American Journal of Hospice and Palliative Medicine, May 1, 2001; 18(3): 187 - 192.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S M Gold, C Heesen, H Schulz, U Guder, A Monch, J Gbadamosi, C Buhmann, and K H Schulz
Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS)
Multiple Sclerosis, April 1, 2001; 7(2): 119 - 130.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R Bakshi, Z A Shaikh, R S Miletich, D Czarnecki, J Dmochowski, K Henschel, V Janardhan, N Dubey, and P R Kinkel
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability
Multiple Sclerosis, June 1, 2000; 6(3): 181 - 185.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. lriarte, M. L Subira, and P. de Castro
Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors
Multiple Sclerosis, April 1, 2000; 6(2): 124 - 130.
[Abstract] [PDF]

Home page
 Mult SclerHome page
D. C Kroencke, S. G Lynch, and D. R Denney
Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern
Multiple Sclerosis, April 1, 2000; 6(2): 131 - 136.
[Abstract] [PDF]

Home page
 NeurologyHome page
R. Bakshi, R. S. Miletich, K. Henschel, Z. A. Shaikh, V. Janardhan, M. Wasay, L. M. Stengel, R. Ekes, and P. R. Kinkel
Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients
Neurology, September 1, 1999; 53(5): 1151 - 1151.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
P. F Smith and C. L Darlington
Recent developments in drug therapy for multiple sclerosis
Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Iriarte, G Katsamakis, and P De Castro
The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis
Multiple Sclerosis, February 1, 1999; 5(1): 010 - 16.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D T WADE
Services for patients with multiple sclerosis
J. Neurol. Neurosurg. Psychiatry, September 1, 1997; 63(3): 275 - 278.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.